Eagle Pharmaceuticals, Inc. Reports Second Quarter 2019 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Eagle Pharmaceuticals (EGRX) Tops Q2 EPS by 3c, Revenues Beat
August 8, 2019 6:55 AM EDTEagle Pharmaceuticals (NASDAQ: EGRX) reported Q2 EPS of $0.86, $0.03 better than the analyst estimate of $0.83. Revenue for the quarter came in at $56.7 million versus the consensus estimate of $53.59 million.
Highlights include:
Adjusted EBITDA for the first quarter of Fiscal 2020 was $86.8 million, which includes an $11.2 million loss related to our Refined Products and Renewables segment for the period, compared to $80.3 million for the first quarter of... More